Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
J Natl Cancer Inst
    July 2021
  1. YEH JM, Lowry KP, Schechter CB, Diller LR, et al
    Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness.
    J Natl Cancer Inst. 2021 Jul 29. pii: 6330765. doi: 10.1093.
    >> Share

  2. WHITE J
    Benefit vs Harm of Internal Mammary Node Irradiation for Node-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329830. doi: 10.1093.
    >> Share

  3. POORTMANS PM, Struikmans H, De Brouwer P, Weltens C, et al
    Side-ffects 15 Years after Lymph Node Irradiation in Breast Cancer: Randomized EORTC Trial 22922/10925.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329829. doi: 10.1093.
    >> Share

  4. PAN IW, Oeffinger KC, Shih YT
    Cost-Sharing and Out-of-Pocket Cost for Women Who Received MRI for Breast Cancer Screening.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329641. doi: 10.1093.
    >> Share

  5. BADVE SS, Penault-Llorca F, Reis-Filho JS, Deurloo R, et al
    Determining PD-L1 Status in Patients with Triple-Negative Breast Cancer: Lessons Learned from IMpassion130.
    J Natl Cancer Inst. 2021 Jul 20. pii: 6324819. doi: 10.1093.
    >> Share

  6. ALAGOZ O, Lowry KP, Kurian AW, Mandelblatt JS, et al
    Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling.
    J Natl Cancer Inst. 2021 Jul 14. pii: 6319940. doi: 10.1093.
    >> Share

  7. SEMBA T, Wang X, Xie X, Cohen EN, et al
    Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated with an Immunosuppressive Tumor Microenvironment.
    J Natl Cancer Inst. 2021 Jul 12. pii: 6313157. doi: 10.1093.
    >> Share

    June 2021
  8. VINAYAK S, Davidson NE
    Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought?
    J Natl Cancer Inst. 2021 Jun 8. pii: 6292091. doi: 10.1093.
    >> Share

  9. DACKUS GM, Jozwiak K, Sonke GS, van der Wall E, et al
    Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients.
    J Natl Cancer Inst. 2021 Jun 8. pii: 6292098. doi: 10.1093.
    >> Share

  10. RUGO HS, Loi S, Adams S, Schmid P, et al
    PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2021 Jun 7. pii: 6294407. doi: 10.1093.
    >> Share

    May 2021
  11. WAGNER LI, Tooze JA, Hall DL, Levine BJ, et al
    Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results from the FoRtitude Randomized Trial.
    J Natl Cancer Inst. 2021 May 31. pii: 6290009. doi: 10.1093.
    >> Share

  12. CUI W, Francis PA, Loi S, Hickey M, et al
    Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
    J Natl Cancer Inst. 2021 May 28. pii: 6287661. doi: 10.1093.
    >> Share

  13. KANTOR O, King TA, Shak S, Russell CA, et al
    Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 May 19. pii: 6278359. doi: 10.1093.
    >> Share

  14. ZHANG J, Yang M
    RE: Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group.
    J Natl Cancer Inst. 2021 May 18. pii: 6277733. doi: 10.1093.
    >> Share

    April 2021
  15. HERSCH J, Barratt A, McGeechan K, Jansen J, et al
    Informing Women About Overdetection in Breast Cancer Screening: Two-year Outcomes from a Randomized Trial.
    J Natl Cancer Inst. 2021 Apr 19. pii: 6237906. doi: 10.1093.
    >> Share

  16. FEIGELSON HS, Bodelon C, Powers JD, Curtis RE, et al
    Body Mass Index and Risk of Second Cancer among Women with Breast Cancer.
    J Natl Cancer Inst. 2021 Apr 5. pii: 6210655. doi: 10.1093.
    >> Share

  17. DEKKER J, Stege CAM, Versteeg KS
    Re: Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2021 Apr 5. pii: 6210765. doi: 10.1093.
    >> Share

  18. RICHMAN IB, Long JB, Hoag JR, Upneja A, et al
    Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening among Women 40-64 Years Old.
    J Natl Cancer Inst. 2021 Apr 3. pii: 6209735. doi: 10.1093.
    >> Share

  19. YU KD, Ge JY, Liu XY, Mo M, et al
    Cyclophosphamide-free Adjuvant Chemotherapy for Ovarian Protection in Young Women with Breast Cancer: a Randomized Phase 3 Trial.
    J Natl Cancer Inst. 2021 Apr 2. pii: 6209077. doi: 10.1093.
    >> Share

  20. LAMBERTINI M, Partridge AH
    Cyclophosphamide-free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women with Breast Cancer.
    J Natl Cancer Inst. 2021 Apr 2. pii: 6209078. doi: 10.1093.
    >> Share

    March 2021
  21. POLLEY MC
    On the Quest of Risk Stratification in HER2-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Mar 31. pii: 6206391. doi: 10.1093.
    >> Share

  22. CHIC N, Luen SJ, Nuciforo P, Salgado R, et al
    Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Mar 31. pii: 6206389. doi: 10.1093.
    >> Share

  23. PISANO ED, Gatsonis C, Sparano J, Troester MA, et al
    RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2021 Mar 30. pii: 6203812. doi: 10.1093.
    >> Share

  24. REINER AS, Watt GP, John EM, Lynch CF, et al
    Smoking, Radiation Therapy, and Contralateral Breast Cancer Risk in Young Women.
    J Natl Cancer Inst. 2021 Mar 29. pii: 6199433. doi: 10.1093.
    >> Share

  25. DU Z, Gao G, Adedokun B, Ahearn T, et al
    Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.
    J Natl Cancer Inst. 2021 Mar 26. pii: 6189099. doi: 10.1093.
    >> Share

  26. HOULAHAN KE
    Do Breast Cancer Risk Scores Work for You?
    J Natl Cancer Inst. 2021 Mar 25. pii: 6189097. doi: 10.1093.
    >> Share

    February 2021
  27. LOHMANN AE, Soldera SV, Pimentel I, Ribnikar D, et al
    Association of Obesity with Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
    J Natl Cancer Inst. 2021 Feb 23. pii: 6147022. doi: 10.1093.
    >> Share

  28. EMENS LA, Molinero L, Loi S, Rugo HS, et al
    Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    J Natl Cancer Inst. 2021 Feb 1. pii: 6125365. doi: 10.1093.
    >> Share

  29. LIM B
    PD-L1 in Breast Cancer: The oad to the erfect iomarker is raught with ncertainty.
    J Natl Cancer Inst. 2021 Feb 1. pii: 6125363. doi: 10.1093.
    >> Share

  30. BLAES A, Konety S, Zordoky B
    Response to Schoormans.
    J Natl Cancer Inst. 2021;113:214-215.
    >> Share

  31. PIMENTEL I, Chen BE, Lohmann AE, Ennis M, et al
    The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.
    J Natl Cancer Inst. 2021;113:192-198.
    >> Share

    January 2021
  32. VAN RAVESTEYN NT, Schechter CB, Hampton JM, Alagoz O, et al
    Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women.
    J Natl Cancer Inst. 2021 Jan 30. pii: 6124199. doi: 10.1093.
    >> Share

  33. PACE LE, Keating NL
    Should Women at Lower-Than-Average Risk of Breast Cancer Undergo Less Frequent Screening?
    J Natl Cancer Inst. 2021 Jan 30. pii: 6124198. doi: 10.1093.
    >> Share

  34. TRAPANI D, Yves Douillard J, Winer EP, Burstein H, et al
    The global landscape of treatment standards for breast cancer.
    J Natl Cancer Inst. 2021 Jan 27. pii: 6120790. doi: 10.1093.
    >> Share

  35. MANDELBLATT JS, Zhou X, Small BJ, Ahn J, et al
    Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2021 Jan 23. pii: 6117333. doi: 10.1093.
    >> Share

  36. FARBER R, Houssami N, Wortley S, Jacklyn G, et al
    Impact of Full-Field Digital Mammography Versus Film-Screen Mammography in Population Screening: A Meta-Analysis.
    J Natl Cancer Inst. 2021;113:16-26.
    >> Share

  37. BRAWLEY OW, Paller CJ
    Overdiagnosis in the Age of Digital Cancer Screening.
    J Natl Cancer Inst. 2021;113:1-2.
    >> Share

    December 2020
  38. ALABOUSI M, Wadera A, Kashif Al-Ghita M, Al-Ghetaa RK, et al
    Performance of Digital Breast Tomosynthesis, Synthetic Mammography and Digital Mammography in Breast Cancer Screening: A Systematic Review and Meta-Analysis.
    J Natl Cancer Inst. 2020 Dec 29. pii: 6054799. doi: 10.1093.
    >> Share

  39. BORDE J, Ernst C, Wappenschmidt B, Niederacher D, et al
    Performance of breast cancer polygenic risk scores in 760 female CHEK2 germline mutation carriers.
    J Natl Cancer Inst. 2020 Dec 29. pii: 6054801. doi: 10.1093.
    >> Share

  40. ELMORE JG, Lee CI
    Keeping Pace with Technology Advances in Breast Cancer Screening: Synthetic 2D Images Outperform Digital Mammography.
    J Natl Cancer Inst. 2020 Dec 29. pii: 6054798. doi: 10.1093.
    >> Share

  41. REIS-FILHO JS, Davidson NE
    Ki67 Assessment in Breast Cancer: Are We There yet?
    J Natl Cancer Inst. 2020 Dec 28. pii: 6053793. doi: 10.1093.
    >> Share

  42. NIELSEN TO, Leung SCY, Rimm DL, Dodson A, et al
    Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group.
    J Natl Cancer Inst. 2020 Dec 28. pii: 6053794. doi: 10.1093.
    >> Share

  43. RAKOVITCH E, Sutradhar R, Nofech-Mozes S, Gu S, et al
    21-Gene Assay and Breast Cancer Mortality in Ductal Carcinoma in Situ.
    J Natl Cancer Inst. 2020 Dec 28. pii: 6053792. doi: 10.1093.
    >> Share

  44. HOUGHTON SC, Eliassen H, Tamimi RM, Willett WC, et al
    Central adiposity and subsequent risk of breast cancer by menopause status.
    J Natl Cancer Inst. 2020 Dec 26. pii: 6050830. doi: 10.1093.
    >> Share

  45. CHECK DK, Winn AN, Fergestrom N, Reeder-Hayes KE, et al
    Response to Strassels and Durham.
    J Natl Cancer Inst. 2020;112:1280.
    >> Share

  46. BLAES AH, Dang C
    Trastuzumab: Weighing the Benefits and the Risks.
    J Natl Cancer Inst. 2020;112:1181-1182.
    >> Share

  47. MACINNIS RJ, Knight JA, Chung WK, Milne RL, et al
    Comparing Five-Year and Lifetime Risks of Breast Cancer in the Prospective Family Study Cohort.
    J Natl Cancer Inst. 2020 Dec 10. pii: 6029579. doi: 10.1093.
    >> Share

  48. ETZIONI R, Shen Y, Shih YT
    Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective.
    J Natl Cancer Inst. 2020 Dec 10. pii: 6029577. doi: 10.1093.
    >> Share

    November 2020
  49. KERLIKOWSKE K, Bissell MCS, Sprague BL, Buist DSM, et al
    Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2020 Nov 10. pii: 5970482. doi: 10.1093.
    >> Share

  50. MA D, Chen SY, Ren JX, Pei YC, et al
    Molecular features and functional implications of germline variants in triple-negative breast cancer.
    J Natl Cancer Inst. 2020 Nov 5. pii: 5956725. doi: 10.1093.
    >> Share

  51. YADAV S, LaDuca H, Polley EC, Hu C, et al
    Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer.
    J Natl Cancer Inst. 2020 Nov 4. pii: 5955835. doi: 10.1093.
    >> Share

  52. COLDITZ GA, Toriola AT
    Refining the focus on early life and adolescent pathways to prevent breast cancer.
    J Natl Cancer Inst. 2020 Nov 2. pii: 5951178. doi: 10.1093.
    >> Share

  53. HOFVIND S, Sebuodegard S, Botteri E
    Response to Zahl.
    J Natl Cancer Inst. 2020;112:1175.
    >> Share

    October 2020
  54. SCHOORMANS D
    RE: Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship.
    J Natl Cancer Inst. 2020 Oct 15. pii: 5924374. doi: 10.1093.
    >> Share

    September 2020
  55. DIGNAM JJ
    Disparities in Breast Cancer: Narrowing the Gap.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912531. doi: 10.1093.
    >> Share

  56. ZAHL PH
    RE: Breast cancer mortality after implementation of organized population-based screening in Norway.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912532. doi: 10.1093.
    >> Share

  57. ALBAIN KS, Gray RJ, Makower DF, Faghih A, et al
    Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912534. doi: 10.1093.
    >> Share

  58. STRASSELS SA, Durham DD
    Re: Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer.
    J Natl Cancer Inst. 2020 Sep 21. pii: 5909658. doi: 10.1093.
    >> Share


  59. Correction: Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank.
    J Natl Cancer Inst. 2020 Sep 15. pii: 5906112. doi: 10.1093.
    >> Share

  60. JATOI I, Pinsky PF
    Breast Cancer Screening Trials: Endpoints and Over-diagnosis.
    J Natl Cancer Inst. 2020 Sep 8. pii: 5902831. doi: 10.1093.
    >> Share


  61. Corrigendum: Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    J Natl Cancer Inst. 2020 Sep 3. pii: 5901262. doi: 10.1093.
    >> Share

  62. HELZLSOUER KJ, Reedy J
    Data Sharing for the Public Good.
    J Natl Cancer Inst. 2020;112:867-868.
    >> Share

    August 2020
  63. VAN DEN BROEK JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, et al
    Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
    J Natl Cancer Inst. 2020 Aug 27. pii: 5898201. doi: 10.1093.
    >> Share

  64. MAGUIRE S, Perraki E, Tomczyk K, Jones ME, et al
    Common susceptibility loci for male breast cancer.
    J Natl Cancer Inst. 2020 Aug 12. pii: 5885091. doi: 10.1093.
    >> Share

  65. MAGBANUA MJM, Hendrix LH, Hyslop T, Barry WT, et al
    Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.
    J Natl Cancer Inst. 2020 Aug 8. pii: 5889954. doi: 10.1093.
    >> Share

  66. FRANZOI MA, Eiger D, Ameye L, Ponde N, et al
    Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy.
    J Natl Cancer Inst. 2020 Aug 4. pii: 5880554. doi: 10.1093.
    >> Share

  67. ANURAG M, Ellis MJ
    Response to Jezequel, Patsouris, Guette, et al.
    J Natl Cancer Inst. 2020;112:865.
    >> Share

    July 2020
  68. RAMIN C, Schaeffer ML, Zheng Z, Connor AE, et al
    All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort.
    J Natl Cancer Inst. 2020 Jul 7. pii: 5868410. doi: 10.1093.
    >> Share

  69. BLAES AH, Konety SH
    Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship.
    J Natl Cancer Inst. 2020 Jul 7. pii: 5868411. doi: 10.1093.
    >> Share

  70. FLORIS G, Richard F, Hamy AS, Jongen L, et al
    Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2020 Jul 6. pii: 5867914. doi: 10.1093.
    >> Share

  71. LOHMANN AE, Goodwin PJ
    Obesity and Breast Cancer: Expanding the Hypothesis Space.
    J Natl Cancer Inst. 2020 Jul 6. pii: 5867915. doi: 10.1093.
    >> Share

  72. BENEFIELD HC, Allott EH, Reeder-Hayes KE, Perou CM, et al
    Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women.
    J Natl Cancer Inst. 2020;112:728-736.
    >> Share

    June 2020
  73. O'LEARY B, Cutts RJ, Huang X, Hrebien S, et al
    Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    J Natl Cancer Inst. 2020 Jun 17. pii: 5858980. doi: 10.1093.
    >> Share

    May 2020
  74. FREEDMAN RA, Sedrak MS, Bellon JR, Block CC, et al
    Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond.
    J Natl Cancer Inst. 2020 May 25. pii: 5843796. doi: 10.1093.
    >> Share

  75. MCCARTHY AM, Armstrong K
    Genetic Testing May Help Reduce Breast Cancer Disparities for African American Women.
    J Natl Cancer Inst. 2020 May 19. pii: 5838710. doi: 10.1093.
    >> Share

  76. PALMER JR, Polley EC, Hu C, John EM, et al
    Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women.
    J Natl Cancer Inst. 2020 May 19. pii: 5838706. doi: 10.1093.
    >> Share

  77. SCHETTINI F, Giudici F, Giuliano M, Cristofanilli M, et al
    Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis.
    J Natl Cancer Inst. 2020 May 14. pii: 5837114. doi: 10.1093.
    >> Share

  78. KAPOOR PM, Mavaddat N, Choudhury PP, Wilcox AN, et al
    Combined associations of a polygenic risk score and classical risk factors with breast cancer risk.
    J Natl Cancer Inst. 2020 May 2. pii: 5828224. doi: 10.1093.
    >> Share

  79. LIN CH, Yap YS, Lee KH, Yeo W, et al
    Response to Sung, Rosenberg, and Yang.
    J Natl Cancer Inst. 2020;112:547-548.
    >> Share

    April 2020
  80. RUSHTON M, Lima I, Tuna M, Johnson C, et al
    Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada.
    J Natl Cancer Inst. 2020 Apr 28. pii: 5826355. doi: 10.1093.
    >> Share

  81. IZCI H, Tambuyzer T, Tuand K, Depoorter V, et al
    A Systematic Review of Estimating Breast Cancer Recurrence at the Population-Level with Administrative Data.
    J Natl Cancer Inst. 2020 Apr 7. pii: 5817318. doi: 10.1093.
    >> Share

  82. CANNIOTO RA, Hutson A, Dighe S, McCann W, et al
    Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival.
    J Natl Cancer Inst. 2020 Apr 2. pii: 5814214. doi: 10.1093.
    >> Share

  83. CHIARELLI AM, Blackmore KM, Mirea L, Done SJ, et al
    Annual vs Biennial Screening: Diagnostic Accuracy Among Concurrent Cohorts Within the Ontario Breast Screening Program.
    J Natl Cancer Inst. 2020;112:400-409.
    >> Share

    March 2020
  84. JEZEQUEL P, Patsouris A, Guette C, Juin PP, et al
    RE: Immune checkpoint profiles in luminal B breast cancer (Alliance).
    J Natl Cancer Inst. 2020 Mar 19. pii: 5810085. doi: 10.1093.
    >> Share

  85. REINER AS, Robson ME, Mellemkjaer L, Tischkowitz M, et al
    Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants, and risk of contralateral breast cancer.
    J Natl Cancer Inst. 2020 Mar 2. pii: 5771357. doi: 10.1093.
    >> Share

    February 2020
  86. YANG X, Song H, Leslie G, Engel C, et al
    Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D.
    J Natl Cancer Inst. 2020 Feb 28. pii: 5764125. doi: 10.1093.
    >> Share

  87. TERAS LR, Patel AV, Smith-Warner SA
    Re: Sustained weight loss and risk of breast cancer in women >/=50 years - Authors' Reply.
    J Natl Cancer Inst. 2020 Feb 26. pii: 5758264. doi: 10.1093.
    >> Share

  88. FLEGAL KM
    Re: Sustained weight loss and risk of breast cancer in women >/=50 years: a pooled analysis of prospective data.
    J Natl Cancer Inst. 2020 Feb 26. pii: 5758265. doi: 10.1093.
    >> Share

  89. HU C, Polley EC, Yadav S, Lilyquist J, et al
    The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort.
    J Natl Cancer Inst. 2020 Feb 24. pii: 5753953. doi: 10.1093.
    >> Share

  90. YAFFE MJ, Mainprize JG
    The Value of All-Cause Mortality as a Metric for Assessing Breast Cancer Screening.
    J Natl Cancer Inst. 2020 Feb 14. pii: 5736137. doi: 10.1093.
    >> Share

  91. HABEL LA, Buist DSM
    Re: Cancer Outcomes in DCIS Patients Without Locoregional Treatment.
    J Natl Cancer Inst. 2020;112:214-215.
    >> Share

  92. CHIARELLI AM, Blackmore KM, Muradali D, Done SJ, et al
    Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program.
    J Natl Cancer Inst. 2020;112:136-144.
    >> Share

    January 2020
  93. ARTHUR RS, Wang T, Xue X, Kamensky V, et al
    Genetic factors, adherence to healthy lifestyle behavior, and risk of invasive breast cancer among women in the UK Biobank.
    J Natl Cancer Inst. 2020 Jan 3. pii: 5695712. doi: 10.1093.
    >> Share

    December 2019
  94. SEBUODEGARD S, Botteri E, Hofvind S
    Breast cancer mortality after implementation of organized population-based breast cancer screening in Norway.
    J Natl Cancer Inst. 2019 Dec 17. pii: 5678884. doi: 10.1093.
    >> Share

  95. TERAS LR, Patel AV, Wang M, Yaun SS, et al
    Sustained weight loss and risk of breast cancer in women >/=50 years: a pooled analysis of prospective data.
    J Natl Cancer Inst. 2019 Dec 13. pii: 5675519. doi: 10.1093.
    >> Share

    November 2019
  96. BRUFSKY A, Mathew A
    Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does It Matter?
    J Natl Cancer Inst. 2019 Nov 6. pii: 5613898. doi: 10.1093.
    >> Share

    October 2019
  97. GRALOW JR, Barlow WE, Paterson AHG, Miao JL, et al
    Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307.
    J Natl Cancer Inst. 2019 Oct 31. pii: 5613900. doi: 10.1093.
    >> Share

  98. ANURAG M, Zhu M, Huang C, Vasaikar S, et al
    Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
    J Natl Cancer Inst. 2019 Oct 30. pii: 5610076. doi: 10.1093.
    >> Share

  99. BARECHE Y, Buisseret L, Gruosso T, Girard E, et al
    Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach.
    J Natl Cancer Inst. 2019 Oct 29. pii: 5609116. doi: 10.1093.
    >> Share

  100. BRAUNSTEIN LZ, Riaz N
    Microenvironmental heterogeneity among triple negative breast cancer subtypes and the promise of precision medicine.
    J Natl Cancer Inst. 2019 Oct 29. pii: 5609117. doi: 10.1093.
    >> Share

  101. HEY SP, Gyawali B, D'Andrea E, Kanagaraj M, et al
    A Systematic Review and Meta-analysis of Bevacizumab in First-line Metastatic Breast Cancer: Lessons for the Research and Regulatory Enterprises.
    J Natl Cancer Inst. 2019 Oct 25. pii: 5607300. doi: 10.1093.
    >> Share

  102. TORRES MA, Gogineni K, Howard DH
    Intensity-modulated radiation therapy in breast cancer patients following the release of a Choosing Wisely recommendation.
    J Natl Cancer Inst. 2019 Oct 24. pii: 5606721. doi: 10.1093.
    >> Share

  103. SMITH GL, Smith BD
    Sea Change: A Decade of IMRT for Treatment of Breast Cancer.
    J Natl Cancer Inst. 2019 Oct 24. pii: 5606720. doi: 10.1093.
    >> Share

  104. RUDDY KJ, Herrin J, Sangaralingham L, Freedman RA, et al
    Follow-up care for breast cancer survivors.
    J Natl Cancer Inst. 2019 Oct 15. pii: 5587764. doi: 10.1093.
    >> Share

  105. FREEDMAN RA, Winer EP
    Adjuvant chemotherapy for older patients with breast cancer: When is the pain worth the gain?
    J Natl Cancer Inst. 2019 Oct 15. pii: 5573122. doi: 10.1093.
    >> Share

  106. CHANDLER Y, Jayasekera J, Schechter C, Isaacs C, et al
    Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.
    J Natl Cancer Inst. 2019 Oct 15. pii: 5573123. doi: 10.1093.
    >> Share

  107. CHECK DK, Winn AN, Fergestrom N, Reeder-Hayes KE, et al
    Concurrent Opioid and Benzodiazepine Prescriptions among Older Women Diagnosed with Breast Cancer.
    J Natl Cancer Inst. 2019 Oct 12. pii: 5586329. doi: 10.1093.
    >> Share

  108. SPENCER JC, Rotter JS, Eberth JM, Zahnd WE, et al
    Employment changes following breast cancer diagnosis: the effects of race and place.
    J Natl Cancer Inst. 2019 Oct 10. pii: 5585013. doi: 10.1093.
    >> Share

  109. DEKKERS JF, Whittle JR, Vaillant F, Chen HR, et al
    Modeling breast cancer using CRISPR/Cas9-mediated engineering of human breast organoids.
    J Natl Cancer Inst. 2019 Oct 7. pii: 5582651. doi: 10.1093.
    >> Share

  110. MACINNIS RJ, Liao Y, Knight JA, Milne RL, et al
    Considerations when using breast cancer risk models for women with negative BRCA1/BRCA2 mutation results.
    J Natl Cancer Inst. 2019 Oct 4. pii: 5581413. doi: 10.1093.
    >> Share

    September 2019
  111. MCCARTHY AM, Guan Z, Welch M, Griffin ME, et al
    Performance of breast cancer risk assessment models in a large mammography cohort.
    J Natl Cancer Inst. 2019 Sep 26. pii: 5574009. doi: 10.1093.
    >> Share

  112. GAIL MH
    Choosing Breast Cancer Risk Models: Importance of Independent Validation.
    J Natl Cancer Inst. 2019 Sep 26. pii: 5574008. doi: 10.1093.
    >> Share

  113. PALMER JR
    Polygenic risk scores for breast cancer risk prediction: Lessons learned and future opportunities.
    J Natl Cancer Inst. 2019 Sep 25. pii: 5573761. doi: 10.1093.
    >> Share

  114. SHIEH Y, Fejerman L, Lott PC, Marker K, et al
    A polygenic risk score for breast cancer in U.S. Latinas and Latin-American women.
    J Natl Cancer Inst. 2019 Sep 25. pii: 5573760. doi: 10.1093.
    >> Share

  115. SUNG H, Rosenberg PS, Yang XR
    Re: Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population.
    J Natl Cancer Inst. 2019 Sep 23. pii: 5572664. doi: 10.1093.
    >> Share

  116. LOWRY KP, Trentham-Dietz A, Schechter CB, Alagoz O, et al
    Long-term Outcomes and Cost-effectiveness of Breast Cancer Screening with Digital Breast Tomosynthesis in the United States.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5567105. doi: 10.1093.
    >> Share

  117. FAHRMANN JF, Vykoukal J, Fleury A, Tripathi S, et al
    Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5567103. doi: 10.1093.
    >> Share

  118. SHIH YT, Shen Y
    Time to Consider a Personalized Approach to Incorporate Tomosynthesis into Routine Breast Cancer Screening.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5567104. doi: 10.1093.
    >> Share

  119. DEMB J, Abraham L, Miglioretti DL, Sprague BL, et al
    Screening mammography outcomes: risk of breast cancer and mortality by comorbidity score and age.
    J Natl Cancer Inst. 2019 Sep 6. pii: 5556084. doi: 10.1093.
    >> Share

    August 2019
  120. COMEN EA, Bowman RL, Selenica P, Kleppe M, et al
    Evaluating clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies.
    J Natl Cancer Inst. 2019 Aug 27. pii: 5555367. doi: 10.1093.
    >> Share

  121. SPERLING AS, Ebert BL
    CHIPing away at breast cancer.
    J Natl Cancer Inst. 2019 Aug 27. pii: 5555366. doi: 10.1093.
    >> Share

    July 2019
  122. AZAM S, Eriksson M, Sjolander A, Hellgren R, et al
    Mammographic Density Change and Risk of Breast Cancer.
    J Natl Cancer Inst. 2019 Jul 12. pii: 5531652. doi: 10.1093.
    >> Share

  123. BARLOW WE, Beaber EF, Geller BM, Kamineni A, et al
    Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium.
    J Natl Cancer Inst. 2019 Jul 11. pii: 5530599. doi: 10.1093.
    >> Share

    June 2019
  124. SACCARELLI CR, Bitencourt AGV, Morris EA
    Breast cancer screening in high-risk women: is MRI alone enough?
    J Natl Cancer Inst. 2019 Jun 24. pii: 5522375. doi: 10.1093.
    >> Share

  125. ROSSI PG, Paci E
    RE: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    J Natl Cancer Inst. 2019 Jun 19. pii: 5520439. doi: 10.1093.
    >> Share

  126. GUI Y, Liu X, Chen X, Yang X, et al
    A network meta-analysis of surgical treatment in patients with early breast cancer.
    J Natl Cancer Inst. 2019 Jun 11. pii: 5514059. doi: 10.1093.
    >> Share

  127. DI COSIMO S, Torri V, Porcu L
    RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2019 Jun 11. pii: 5514057. doi: 10.1093.
    >> Share

  128. CHOUDHURY PP, Wilcox AN, Brook MN, Zhang Y, et al
    Comparative validation of breast cancer risk prediction models and projections for future risk stratification.
    J Natl Cancer Inst. 2019 Jun 4. pii: 5511406. doi: 10.1093.
    >> Share

    May 2019
  129. YANG Y, Wu L, Shu XO, Cai Q, et al
    Genetically predicted levels of DNA methylation biomarkers and breast cancer risk: data from 228,951 women of European descent.
    J Natl Cancer Inst. 2019 May 29. pii: 5505447. doi: 10.1093.
    >> Share

  130. SU Y, Huang J, Wang S, Unger JM, et al
    The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
    J Natl Cancer Inst. 2019 May 15. pii: 5489913. doi: 10.1093.
    >> Share

  131. GOMEZ SL, Yao S, Kushi LH, Kurian AW, et al
    Is breast cancer in Asian and Asian American women a different disease?
    J Natl Cancer Inst. 2019 May 15. pii: 5489912. doi: 10.1093.
    >> Share

  132. LIN CH, Yap YS, Lee KH, Im SA, et al
    Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population.
    J Natl Cancer Inst. 2019 May 15. pii: 5489914. doi: 10.1093.
    >> Share

  133. TESSIER L, Furzer J, Hodgson D, Cotton C, et al
    Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin's Lymphoma.
    J Natl Cancer Inst. 2019 May 9. pii: 5485250. doi: 10.1093.
    >> Share

    April 2019
  134. PRAT A, Pascual T, De Angelis C, Gutierrez C, et al
    HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.
    J Natl Cancer Inst. 2019 Apr 30. pii: 5475264. doi: 10.1093.
    >> Share

  135. MARIOTTO A, Jayasekerea J, Petkov V, Schechter CB, et al
    Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    J Natl Cancer Inst. 2019 Apr 24. pii: 5475265. doi: 10.1093.
    >> Share

  136. MUKHOPADHYAY UK, Oturkar CC, Adams C, Wickramasekera N, et al
    TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452444. doi: 10.1093.
    >> Share

  137. BADVE S, Gokmen-Polar Y
    TP53 Status and Estrogen Receptor-beta in Triple Negative Breast Cancer: Company matters.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452445. doi: 10.1093.
    >> Share

  138. XU Z, Sandler DP, Taylor JA
    Blood DNA methylation and breast cancer: A prospective case-cohort analysis in the Sister Study.
    J Natl Cancer Inst. 2019 Apr 15. pii: 5466458. doi: 10.1093.
    >> Share

  139. LI N, McInerny S, Zethoven M, Cheasley D, et al
    Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
    J Natl Cancer Inst. 2019 Apr 5. pii: 5428180. doi: 10.1093.
    >> Share

    March 2019
  140. KIM RS, Song N, Gavin PG, Salgado R, et al
    Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.
    J Natl Cancer Inst. 2019 Mar 19. pii: 5393262. doi: 10.1093.
    >> Share

  141. RODRIGUEZ-RUIZ A, Lang K, Gubern-Merida A, Broeders M, et al
    Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists.
    J Natl Cancer Inst. 2019 Mar 5. pii: 5307077. doi: 10.1093.
    >> Share

    February 2019
  142. KRESOVICH JK, Xu Z, O'Brien KM, Weinberg CR, et al
    Methylation-based biological age and breast cancer risk.
    J Natl Cancer Inst. 2019 Feb 22. pii: 5341521. doi: 10.1093.
    >> Share

  143. NGUYEN B, Veys I, Leduc S, Bareche Y, et al
    Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.
    J Natl Cancer Inst. 2019 Feb 21. pii: 5355042. doi: 10.1093.
    >> Share

  144. COHN BA, Cirillo PM, Terry MB
    DDT and Breast Cancer: Prospective Study of Induction Time and Susceptibility Windows.
    J Natl Cancer Inst. 2019 Feb 13. pii: 5299924. doi: 10.1093.
    >> Share

  145. LEE CI, Elmore JG
    Artificial Intelligence for Breast Cancer Imaging: The New Frontier?
    J Natl Cancer Inst. 2019 Feb 5. pii: 5307046. doi: 10.1093.
    >> Share

    January 2019
  146. ABDEL-QADIR H, Thavendiranathan P, Austin PC, Lee DS, et al
    The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304781. doi: 10.1093.
    >> Share

  147. LENIHAN DJ
    Cardiac Disease After Breast Cancer Treatment: Make Sure to Check Our Blind Spot!
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304780. doi: 10.1093.
    >> Share

  148. KRAMER I, Schaapveld M, Oldenburg HSA, Sonke GS, et al
    The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype.
    J Natl Cancer Inst. 2019 Jan 30. pii: 5304371. doi: 10.1093.
    >> Share

  149. CHEUNG KJ, Davidson NE
    Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.
    J Natl Cancer Inst. 2019 Jan 28. pii: 5303805. doi: 10.1093.
    >> Share

  150. PAREJA F, Lee JY, Brown DN, Piscuoglio S, et al
    The Genomic Landscape of Mucinous Breast Cancer.
    J Natl Cancer Inst. 2019 Jan 11. pii: 5288408. doi: 10.1093.
    >> Share

  151. REEVES KW, Santana MD, Manson JE, Hankinson SE, et al
    Urinary Phthalate Biomarker Concentrations and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284913. doi: 10.1093.
    >> Share

  152. HUILLARD O, Le Strat Y, Dubertret C, Goldwasser F, et al
    RE: Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284914. doi: 10.1093.
    >> Share

  153. SPRAGUE BL, Kerlikowske K, Bowles EJA, Rauscher GH, et al
    Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2019 Jan 8. pii: 5280767. doi: 10.1093.
    >> Share

    November 2018
  154. TERRY MB, Daly MB, Phillips KA, Ma X, et al
    Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    J Natl Cancer Inst. 2018 Nov 28. pii: 5212812. doi: 10.1093.
    >> Share

  155. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5193772. doi: 10.1093.
    >> Share

  156. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5342932. doi: 10.1093.
    >> Share

  157. KENSLER KH, Poole EM, Heng YJ, Collins LC, et al
    Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
    J Natl Cancer Inst. 2018 Nov 15. pii: 5184399. doi: 10.1093.
    >> Share

  158. CARREIRA H, Williams R, Muller M, Harewood R, et al
    Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review.
    J Natl Cancer Inst. 2018 Nov 7. pii: 5164282. doi: 10.1093.
    >> Share

    October 2018
  159. QIAN F, Wang S, Mitchell J, McGuffog L, et al
    Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
    J Natl Cancer Inst. 2018 Oct 12. pii: 5128773. doi: 10.1093.
    >> Share

  160. TRAPP E, Janni W, Schindlbeck C, Juckstock J, et al
    Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127124. doi: 10.1093.
    >> Share

  161. SPARANO JA, Henry NL
    Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127122. doi: 10.1093.
    >> Share

  162. DESANTIS CE, Jemal A
    Re: Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Oct 10. pii: 5126439. doi: 10.1093.
    >> Share

    September 2018
  163. LEE JY, Joo HS, Choi HJ, Jin S, et al
    Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 27. pii: 5103386. doi: 10.1093.
    >> Share

  164. HELZLSOUER KJ
    Can Less Be More for Individuals With Low-Risk Breast Cancer?
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101448. doi: 10.1093.
    >> Share

  165. JAYASEKERA J, Schechter CB, Sparano JA, Jagsi R, et al
    Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101449. doi: 10.1093.
    >> Share

    August 2018
  166. MARINOVICH ML, Hunter KE, Macaskill P, Houssami N, et al
    Breast Cancer Screening Using Tomosynthesis or Mammography: A Meta-analysis of Cancer Detection and Recall.
    J Natl Cancer Inst. 2018 Aug 9. pii: 5068658. doi: 10.1093.
    >> Share

  167. SHIMELIS H, LaDuca H, Hu C, Hart SN, et al
    Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
    J Natl Cancer Inst. 2018 Aug 7. pii: 5062996. doi: 10.1093.
    >> Share

    July 2018
  168. DIERAS V, Rugo HS, Schnell P, Gelmon K, et al
    Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
    J Natl Cancer Inst. 2018 Jul 18. pii: 5055701. doi: 10.1093.
    >> Share


  169. Corrigendum to "Cost and Complications of Local Therapies for Early-Stage Breast Cancer".
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054617. doi: 10.1093.
    >> Share

  170. LU DL, Le Cornet C, Sookthai D, Johnson TS, et al
    Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the EPIC-Heidelberg Cohort.
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054612. doi: 10.1093.
    >> Share

  171. DAVIS LYNN BC, Rosenberg PS, Anderson WF, Gierach GL, et al
    Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Jul 5. pii: 5049141. doi: 10.1093.
    >> Share

    June 2018
  172. LAMBERTINI M, Campbell C, Bines J, Korde LA, et al
    Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033460. doi: 10.1093.
    >> Share

  173. CATHCART-RAKE E, Gast KC, Ruddy KJ
    What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033462. doi: 10.1093.
    >> Share


  174. Corrigendum to "Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer".
    J Natl Cancer Inst. 2018;110:684.
    >> Share

    May 2018
  175. PATTERSON RE, Marinac CR, Sears DD, Kerr J, et al
    The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes.
    J Natl Cancer Inst. 2018 May 18. pii: 4999668. doi: 10.1093.
    >> Share

  176. LOHMANN AE, Pimentel I, Goodwin PJ
    Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
    J Natl Cancer Inst. 2018 May 18. pii: 4999672. doi: 10.1093.
    >> Share

    April 2018
  177. DESMEDT C, Demicheli R, Fornili M, Bachir I, et al
    Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
    J Natl Cancer Inst. 2018 Apr 30. pii: 4975381. doi: 10.1093.
    >> Share

  178. JAYASEKERA J, Li Y, Schechter CB, Jagsi R, et al
    Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990602. doi: 10.1093.
    >> Share

  179. BIDARD FC, Michiels S, Riethdorf S, Mueller V, et al
    Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    J Natl Cancer Inst. 2018 Apr 12. pii: 4969338. doi: 10.1093.
    >> Share

  180. CHOI HJ, Joo HS, Won HY, Min KW, et al
    Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    >> Share

  181. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    >> Share

    March 2018
  182. MATIKAS A, Foukakis T, Bergh J
    RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Mar 29. pii: 4956469. doi: 10.1093.
    >> Share

  183. HAWK E, Maresso KC, Brown P
    NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
    J Natl Cancer Inst. 2018 Mar 15. pii: 4938606. doi: 10.1093.
    >> Share

  184. RITZWOLLER DP, Hassett MJ, Uno H, Cronin AM, et al
    Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm.
    J Natl Cancer Inst. 2018;110:273-281.
    >> Share

    February 2018
  185. GAIL MH, Pfeiffer RM
    Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.
    J Natl Cancer Inst. 2018 Feb 27. pii: 4912416. doi: 10.1093.
    >> Share

  186. ZACHARIAE R, Amidi A, Damholdt MF, Clausen CDR, et al
    Internet-Delivered Cognitive-Behavioral Therapy for Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881759. doi: 10.1093.
    >> Share

  187. OESTERREICH S, Lucas PC, McAuliffe PF, Bruno TC, et al
    Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881762. doi: 10.1093.
    >> Share

  188. DESMEDT C, Salgado R, Fornili M, Pruneri G, et al
    Immune Infiltration in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881757. doi: 10.1093.
    >> Share

  189. IRWIN MR
    Innovation in the Treatment of Insomnia in Breast Cancer Survivors.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881761. doi: 10.1093.
    >> Share

  190. BROWN J, Rathbone E, Hinsley S, Gregory W, et al
    Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
    J Natl Cancer Inst. 2018 Feb 7. pii: 4842040. doi: 10.1093.
    >> Share

  191. BANDOS H, Melnikow J, Rivera DR, Swain SM, et al
    Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
    J Natl Cancer Inst. 2018;110.
    >> Share

  192. RIVERA DR, Ganz PA, Weyrich MS, Bandos H, et al
    Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    >> Share

  193. JAGSI R, Momoh AO, Qi J, Hamill JB, et al
    Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.
    J Natl Cancer Inst. 2018;110.
    >> Share

    January 2018
  194. LINDSTROM LS, Yau C, Czene K, Thompson CK, et al
    Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    J Natl Cancer Inst. 2018 Jan 19. pii: 4780395. doi: 10.1093.
    >> Share

  195. OZTURK TOPCU T, Jerzak KJ, Warner E
    RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2018 Jan 10. pii: 4797407. doi: 10.1093.
    >> Share

  196. LASKY-SU JA, Zeleznik OA, Eliassen AH
    Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795354. doi: 10.1093.
    >> Share

  197. MOORE SC, Playdon MC, Sampson JN, Hoover RN, et al
    A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795343. doi: 10.1093.
    >> Share

  198. SCHRIJVER WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, et al
    Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Jan 5. pii: 4791841. doi: 10.1093.
    >> Share

  199. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    J Natl Cancer Inst. 2018;110.
    >> Share

  200. GOLDVASER H, Barnes TA, Seruga B, Cescon DW, et al
    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018;110.
    >> Share

  201. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    >> Share

    December 2017
  202. POORVU PD, Winer EP
    Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718502. doi: 10.1093.
    >> Share

  203. KURIAN AW, Bondarenko I, Jagsi R, Friese CR, et al
    Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718501. doi: 10.1093.
    >> Share

  204. GLUZ O, Nitz U, Liedtke C, Christgen M, et al
    Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
    J Natl Cancer Inst. 2017 Dec 8. pii: 4698155. doi: 10.1093.
    >> Share

    November 2017
  205. BELKACEMI Y, Kuten A
    RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017 Nov 21. pii: 4645256. doi: 10.1093.
    >> Share

  206. MEIER M, Orr N
    Genetic Determinants of Breast Cancer Risk in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2017;109.
    >> Share

  207. MORTON LM, Sampson JN, Armstrong GT, Chen TH, et al
    Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
    J Natl Cancer Inst. 2017;109.
    >> Share

  208. DESHMUKH AA, Shirvani SM, Lal L, Swint JM, et al
    Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    >> Share

  209. SCHWARZ LJ, Hutchinson KE, Rexer BN, Estrada MV, et al
    An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    J Natl Cancer Inst. 2017;109.
    >> Share

    October 2017
  210. LAMBERTINI M, Kroman N, Ameye L, Cordoba O, et al
    Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2017 Oct 26. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016